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episodes on the daily lives of patients with congenital hemophilia
with inhibitors and their caregivers. This analysis of the Dosing
Observational Study in Hemophilia examined the impact of acute
bleeding episodes on work, school, and family activities. Methods:
Patients and caregivers participated in a diary study for 90 or more
days or until patients experienced four bleeding episodes. All bleed
treatments, interference with daily activities, and quality-of-life
assessments were captured in daily records. Patients and caregivers
reported planned workdays or school days eligible to be “lost” so as to
differentiate from days lost because of disability or nonworking
status, weekends, and vacations. Results: Diaries were completed
for 39 patients (18 adults and 21 children). Bleeding episodes that
continued for 3 or more days (16.4%) accounted for most of the major
changes to family plans. For the 38 patients with bleeding episodes,
47% of 491 bleed days fell on planned workdays or school days; theee front matter Copyright & 2014, International S
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97239.remainder fell on weekends, holidays, or nonworkdays or non–
school days and therefore did not count as “lost days.” Patients
reported a loss of productivity on a greater percentage of eligible
bleed days than did caregivers (3.9% vs. 0.8%, respectively). Patients
and caregivers reported 13.5%/9.3% fully missed and 3.5%/7.6%
partially missed days. Conclusions: This study demonstrated that
in hemophilia with inhibitors, bleeding episodes interfere with the
daily activities of patients and their caregivers. Furthermore, doc-
umenting only lost days underestimated the impact of bleeding
episodes because of the high percentage of days without planned
work or school.
Keywords: congenital hemophilia, daily activities, DOSE, inhibitors,
quality of life.
Copyright & 2014, International Society for Pharmacoeconomics and
Outcomes Research (ISPOR). Published by Elsevier Inc.Introduction
Congenital hemophilia is a rare disease that places a considerable
burden on patients and their caregivers. Hemophilia A, a deﬁ-
ciency of coagulation factor VIII, accounts for 85% of the cases;
hemophilia B is less common and results from a deﬁciency of
factor IX [1]. The treatment of congenital hemophilia may be
complicated by the development of inhibitors or alloantibodies to
the clotting factor administered as replacement therapy. Signiﬁ-
cant inhibitors develop in approximately 15% to 30% of the
patients with hemophilia A [2] and in 1% to 3% of the patients
with hemophilia B [1]. Currently, it is estimated that there are 800
to 1000 patients in the United States with congenital hemophilia
complicated by inhibitors [3].
Compared with patients without inhibitors, treating the
bleeding episodes of patients with inhibitors is more complex,with acute bleeding episodes managed effectively with infusions
of bypassing agents (BPAs) such as recombinant activated factor
VII (rFVIIa, NovoSeven RT, Novo Nordisk A/S, Bagsvaerd, Den-
mark) [4] or plasma-derived activated prothrombin complex
concentrates (FEIBA, NF, Baxter AG, Vienna, Austria) [5]. As in
patients with hemophilia without inhibitors, the treatment of
patients with inhibitors has largely switched from the hemo-
philia treatment center (HTC), where the administration of BPAs
is done by HTC staff, to the home, where the administration is
done by the patient or the caregiver [6].
Dosing Observational Study in Hemophilia (DOSE) was a
prospective, multicenter, noninterventional, and observational
diary study designed to examine the use of BPAs—and speciﬁ-
cally rFVIIa—in the home setting [7]; it also evaluated the
correlation of prescribed and actual dosing [8] as well as daily
assessments of health-related quality of life (HRQOL) [9]. DOSEociety for Pharmacoeconomics and Outcomes Research (ISPOR).
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V A L U E I N H E A L T H 1 7 ( 2 0 1 4 ) 7 4 4 – 7 4 8 745also evaluated the impact of bleeding episodes on patient and
caregiver daily activities, absenteeism, and productivity. This
article focuses on the planned secondary analysis of the impact
of hemophilia and bleeding episodes on work or school and on
family activities.Methods
DOSE was conducted between January 2008 and July 2009 at 20
sites in the United States. Its detailed methodology has been
described elsewhere [7], and the primary end point was charac-
terization of treatment of bleeding episodes [8]. HRQOL, burden of
illness, and loss of workdays or school days were evaluated as
planned secondary end points [9]. The study was conducted with
prior approval by local institutional review boards and had the
written consent of the patients or their legal representatives. All
patients completed a paper diary, and optionally, patients could
directly enter information electronically in real time.
To be considered for this analysis, male patients had to have
hemophilia with inhibitors and at least four bleeding episodes in
the previous 3 months, irrespective of whether they were treated
primarily on demand or with prophylaxis. They also needed to be
prescribed rFVIIa as ﬁrst-line therapy for the treatment of bleed-
ing episodes. All patients had existing prescriptions for rFVIIa
and/or other BPAs for the treatment of bleeding, and were
expected to maintain their usual treatment regimens for bleeding
episodes and contact their HTCs as part of their normal routines.
The routine administration of BPAs (e.g., prophylaxis) on non-
bleed days was not recorded. Patients (Z18 years) or caregivers
(of children o18 years) were asked to complete daily diary re-
cords for at least 90 days or until four bleeding episodes were
experienced by the patient [7]. Speciﬁc to this analysis, daily
reports also included whether each day was a planned adult
patient workday or school day, and in the case of caregiver-
completed diaries, independently whether this was a caregiver
workday and/or child’s school day (i.e., a day eligible to be lost) to
account for adult patients and parents who were not working, for
children who were not yet in school, and for weekends and
vacations.
On bleed days, patients and caregivers used a 10-point self-
rating scale to evaluate the interference of bleeding on planned
activities (0 [none] to 10 [worst change ever]) and a novel, explor-
atory four-level categorical scale based on patient and caregiver
focus groups (i.e., did not change schedule or plans at all, slightly
changed schedule, signiﬁcantly rearranged schedule, or major
change in family plans). Absenteeism from planned daily activ-
ities was measured by the percentage of missed or unproductive
bleed days that occurred on planned workdays or school days for
the patient and the caregiver, excluding days on which work or
school was not planned. Statistical analyses were largely descrip-
tive and correlative in nature and were performed by Outcome
Sciences using SAS 9.2 (SAS Institute, Inc., Cary, NC). Given the
limited sample size and the exploratory nature of this analysis,
no intergroup analyses were performed.Results
Patients’ Demographic Characteristics and Hemophilia
History
Patients’ demographic characteristics and history have been
published previously [7–10]. Of 52 patients enrolled, 39 completed
daily diaries (or had diaries completed for them by their care-
givers); the majority had hemophilia A (85%) and were white
(69%). Thirty-seven participants reported using rFVIIa as on-demand–only treatment, 5 were also on immune tolerance
therapy, and 12 reported receiving routine prophylaxis with BPAs
to prevent bleeding [8–10]. For diary completers, the median
(range) age was 16.2 (1.6–60.9) years [8], with 31% being younger
than 11 years and 23% aged 11 to 18 years [7,8]. Participants
reported a median of 13 bleeding episodes within the previous
year [8,9]. Most patients were limited in recreational activities,
work or school, and/or self-care activities; only 28.2% reported an
“unrestricted” functional status [8].
Of 39 diaries (4063 days), 18 were completed by patients (2059
days) and 21 were completed by 19 caregivers (for 21 patients,
2004 days). There were 38 patients who reported 194 bleeding
episodes (491 bleed days; median 8.2% of diary days) [7]; 1 patient
did not report any bleeding episodes during the study period.
Most bleeding episodes (91%) were treated with BPAs; 18 did not
document any treatment with these agents although other treat-
ments such as topical agents could have been used without being
captured in the data set [8].Impact of Bleeding Episodes on Bleed Day Activities
Overall, bleeding episodes lasted a median (range) of 31.0 (1.0–
509.0) hours. For bleeding episodes that lasted 3 or more days
(ranging from 3 to 22 days), there were a total of 187 bleed days
that accounted for 38% of all bleed days. On a 0- to 10-point rating
scale, the median (range) interference of bleeding episodes in
daily activities was 2 (0–10) on the ﬁrst day of a bleed, 3 (0–10) on
the second day of a bleed, and 4 (1–10) on subsequent days. In
categorical ratings, planned activities of patients or caregivers
were affected on less than half of bleed days (46.3% on the ﬁrst
day of bleeding episodes; 39.3% on the second day; 40.4% on
subsequent days). When major changes made to schedules and
family plans were reported, changes occurred more often on days
3 to 22 (16.4%) than on day 1 (3.7%) or day 2 (5.4%) (Fig. 1). On a 10-
point scale of interference in schedule, scores for interference on
day 1, day 2, and day 3þ of a bleeding episode steadily increased,
with median scores of 2.0, 3.0, and 4.0, respectively. Interference
was similar across all bleed types on day 1; however, on days 3 to
22, joint and “other” bleed types interfered more with patient or
caregiver schedules (4.0 and 4.0, respectively) than did muscle
bleeds (1.0).Impact of Bleeding Episodes on Productivity and Loss of Work
or School
For the 38 patients with bleeding episodes reported across 491
bleed days, 230 (47%) bleed days fell on planned workdays or
school days and 182 (79.1%) patients did not miss work or school.
For all patients (adults and children), bleeding resulted in a loss of
productivity at work or school on 9 (3.9%) eligible days and a loss
of full or partial workday or school day on 31 (13.5%) and 8 (3.5%)
days, respectively (Fig. 2A). When considering the underlying
treatment strategy, patients did not miss planned work or school
on 84 of 112 (75.0%) on-demand bleed days and 56 of 69 (81.2%)
prophylaxis breakthrough bleed days. Although not analyzed
statistically, hemarthroses and other bleeds seemed to result in
more lost workdays or school days than did muscle bleeds
(Fig. 2A). For 229 caregiver-reported bleed days, 118 (52%) fell on
planned workdays or school days and on 97 (82.2%) caregivers did
not miss work or school. Caregivers were unproductive at work or
school on 1 (0.8%) eligible day, and they missed full or partial
days of work or school on 11 (9.3%) and 9 (7.6%) days, respectively
(Fig. 2B). When considering the underlying treatment strategy,
caregivers did not miss planned work or school on 30 of 46 (65.2%)
on-demand bleed days and 20 of 25 (80.0%) prophylaxis break-
through bleed days. Although not analyzed statistically, there did
Fig. 1 – Impact of bleeding on daily activities of patients with hemophilia with inhibitors or their caregivers (regardless of
treatment).
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days or school days (Fig. 2B).Discussion
DOSE was designed to understand the decision-making process
that occurred in the home-treatment setting, and to gain insights
from the experience of patients and caregivers with managing
their own or their child’s disease. With the use of daily diary
records, it was observed that, regardless of treatment, bleed days
were associated with signiﬁcantly worse HRQOL than nonbleed
days [9]. Furthermore, adults generally had more chronic arthrop-
athy and thus had a poorer HRQOL than did children [9]. In the
present study, these ﬁndings are further explored by demonstrat-
ing that bleeding episodes affected both patients and caregivers,
with major changes to family plans occurring more frequently
with bleeding episodes that persisted for 3 or more days (i.e.,
presumably a marker for more severe episodes) or when a visit to
the HTC or hospital might occur.
It is generally thought that home treatment of bleeding
episodes may help reduce the burden of disease that results
from interference with daily activities for both patients and
caregivers. In a previous study, patients and caregivers reported
a median of 17.5 and 19.1 missed workdays or school days,
respectively, in the past 12 months because of illness related to
hemophilia [11]. In addition, in the preceding 12 months for
patients and caregivers in this same study, illness led to a median
of 12.5 and 10.0 low-productive days, respectively [11]. Similarly,
DOSE showed that bleed days negatively affected the productivity
of both patients with hemophilia with inhibitors and their care-
givers. When expressed traditionally as a percentage of total
diary days, the impact was perhaps less than anticipated. The
high rate of bleeding episodes falling on nonworkdays or non–
school days in adult patients suggests that long-term disability,
partial employment, underemployment, or unemployment
(related or unrelated to disability) and other factors need to be
considered when assessing the impact of bleeding in clinical
studies and treatment planning. The similarly high rate of
bleeding episodes (50%) falling on nonworkdays or non–school
days for caregivers who may have one or more affected childrento manage at home suggests that a more comprehensive tool for
assessing caregiver burden is needed to assess the burden of
hemophilia on the family. It also highlights the need for qualify-
ing lost school days in young pediatric populations (i.e., aged o5
years) where school is not mandated or available and therefore
there are no lost days in these young patients; however, bleeding
may still place a burden on the family.
Investigators for DOSE asked patients and caregivers whether
a bleed day was a planned workday or school day and if so,
whether they did not miss work or school, missed a partial day of
work or school, missed a full day of work or school, or were
unproductive at work or school. This is similar to the approach
used by the Work Productivity and Activity Impairment (WPAI)
questionnaire, which was originally designed to measure the
effect of general health and symptom severity on work produc-
tivity and regular activities [12] but has since been adapted
for various disease states and now includes a speciﬁc question-
naire for caregivers [13]. The four types of scores yielded by the
WPAI questionnaire are absenteeism (work time missed),
which is similar to this analysis of workdays or school days
missed; presenteeism (impairment at work/reduced on-the-job
effectiveness), for which we measured unproductive days; work
productivity loss (overall work impairment/absenteeism plus
presenteeism); and activity impairment [13]. The WPAI question-
naire obtains a greater level of detail given that it elicits the
number of days and hours worked and missed from work, the
number of days that patients and caregivers found performing
their work difﬁcult, and the extent to which their work was
impaired [12]. Given that this analysis measured the impact on
patients and caregivers through daily diary records, the 7-day
recall period of the WPAI questionnaire would have been less
practical for the present study.
The impact of hemophilia on employment was recently
assessed in the Hemophilia Experiences, Results, and Opportu-
nities study; this study assessed the impact of hemophilia on
employment in 1236 respondents from 10 countries (675 adult
patients [189 from the United States], 561 caregivers of affected
children [190 from the United States]) [14]. Of the respondents,
60% of the adults were employed (72% in the United States) and
81% reported that hemophilia negatively affected their employ-
ment (95% for patients with inhibitors); 72% of the parents were
Fig. 2 – Productivity and loss of workdays or school days in patients with hemophilia with inhibitors or their caregivers. All, all
treatment regimens; ITI, immune tolerance induction therapy; OD, on-demand; PRO, prophylaxis.
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hemophilia negatively affected their employment (76% for
parents of children with inhibitors). Speciﬁc effects on adult
patients included selecting a job or training that takes into
account their hemophilia-related needs or the fact that they
have had to voluntarily leave a job in the past because of their
hemophilia. For parents, speciﬁc negative effects included select-
ing a job or training that took into account having to work ﬂexible
hours in order to care for a child with hemophilia [14]. Neither
DOSE nor the WPAI questionnaire capture any information
regarding the impact of the disease on the patients’ or caregivers’ability to work, on their career choice, or on the speciﬁc effects on
their career.
Data interpretation in the present analysis may be limited by
several factors, including the small population size and the HTC-
based comprehensive care approach. DOSE, however, captured
approximately 5% of the estimated US population of patients
with hemophilia with inhibitors [7]. It is possible that adult
patients who elected to participate, or parents of affected chil-
dren electing to participate, were more likely to be not working
perhaps because they had partners with health insurance cover-
age or because they were simply more negatively affected by the
V A L U E I N H E A L T H 1 7 ( 2 0 1 4 ) 7 4 4 – 7 4 8748burden of treatment. Although the patients’ or caregivers’ partial
employment, underemployment, or unemployment in the United
States during the 2008 through 2009 time period may be hemo-
philia-related, that was also the time of peak unemployment due
to the Great Recession, which might have been a contributing
factor in the number of eligible days for adult patients and
caregivers. This possibility suggests the need for further study,
which would include a more comprehensive assessment of the
impact on parents and affected and unaffected siblings, as well
as on the partners and families of adult patients.
Furthermore, it is plausible that differences exist between
patients treated on-demand and those treated prophylactically
who have breakthrough bleeding at similar rates. Of the 12
patients who were on prophylaxis, 10 were children, which is
consistent with the higher use of prophylaxis in general in
pediatric patients in the United States. At the time of DOSE, no
BPA was approved for prophylaxis; therefore, it was not possible
to prospectively capture differences in the impact on bleed versus
nonbleed days (greater activity, less frequent visits). Furthermore,
most of the bleeding in patients with hemophilia is joint bleed-
ing, which limits the analysis of other bleed types. Ultimately,
this was a small population of patients with great inter- and
intrapatient variability (over time), which limits the ability to
further analyze by potential confounders.Conclusions
DOSE is the ﬁrst study to show that patient diaries can be used to
monitor both the extent to which patients with hemophilia and
caregivers are actively engaged in work or school activities on a
daily basis and the impact of hemophilia and bleeding episodes
on work or school and on family activities. The signiﬁcant
percentage of days documented that were not planned workdays
or school days for patients and parents suggests the limitations
of traditional analyses that examine only lost or unproductive
time. By assessing the impact on the family, DOSE extends the
observations from daily HRQOL assessments that bleed days
affect the patient. Furthermore, bleeding episodes that lasted
for 3 or more days were more likely to have a negative impact, so
future studies should gather more detailed information about
potential changes from home to hospital treatment or the need
for HTC visits due to these longer lasting bleeding episodes.Acknowledgments
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